Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 1, 2011, Pages 87-99

  Merchionne, Francesca ^a   Procaccio, Pasquale ^a   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Autoantibody activity; Clonal B cells; Hyperviscosity syndrome; Lymphoplasmacytic infiltration; Prognostic factors; Tissue deposition; Treatment; Waldenstr m's macroglobulinemia

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ALEMTUZUMAB; ALKYLATING AGENT; BENDAMUSTINE; BETA 2 MICROGLOBULIN; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; HEMOGLOBIN; IMMUNOGLOBULIN M; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; NUCLEOSIDE DERIVATIVE; ONX 09212; PREDNISONE; PROTEIN KINASE B; RESVERATROL; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; WNT PROTEIN;

ACUTE LEUKEMIA; ADULT; AGE; AGED; AMYLOIDOSIS; ANEMIA; ANTIBODY BLOOD LEVEL; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CASE STUDY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS INFECTION; DRESS SYNDROME; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; FEMALE; GENETIC ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HERPES ZOSTER; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA;

HUMANS; PROGNOSIS; WALDENSTROM MACROGLOBULINEMIA;

EID: 80053131388     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.09.007     Document Type: Review

References (85)

1. Waldenström J. Incipient myelomatosis or " essential" hyperglobulinemia with fibrinogenopenia: a new syndrome?. Acta Med Scand 1944, 117:216-222.
2. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
3. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2001, IARC, Lyon, France. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
4. Owen R.G., Treon S.P., Al-Katib A., et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003, 30:110-115.
5. Groves F.D., Travis L.B., Devesa S.S., Ries L.A.G., Fraumeni J.F. Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998, 82:1078-1081.
6. Dimopoulos M.A., Panayiotidis P., Moulopoulos L.A., Sfikakis P., Dalakas M. Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000, 18:1214-1226.
7. Treon S.P., Hunter Z.R., Aggarwal A., et al. Characterization of familial Waldenström's macroglobulinemia. Ann Oncol 2006, 17:488-494.
8. McMaster M.L., Goldin L.R., Bai Y., et al. Genomewide linkage screen for Waldenström macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet 2006, 79:695-701.
9. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003, 102:3759-3764.
10. Santini G.F., Crovatto M., Modolo M.L., et al. Waldenström macroglobulinemia: a role of HCV infection?. Blood 1993, 82:2932.
11. Veneri D., Aqel H., Franchini M., Meneghini V., Krampera M. Prevalence of hepatitis C virus infection in IgM-type monoclonal gammopathy of uncertain significance and Waldenström macroglobulinemia. Am J Hematol 2004, 77:421.
12. Leleu X., O'Connor K., Ho A.W., et al. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol 2007, 82:83-84.
13. Sahota S.S., Forconi F., Ottensmeier C.H., Stevenson F.K. Origins of the malignant clone in typical Waldenström's macroglobulinemia. Semin Oncol 2003, 30:136-141.
14. Martin-Jimenez P., Garcia-Sanz R., Balanzategui A., et al. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica 2007, 92:635-642.
15. Martin-Jimenez P., Garcia-Sanz R., Sarasquete M.E., et al. Functional class switch recombination may occur 'in vivo' in Waldenström macroglobulinaemia. Br J Haematol 2007, 136:114-116.
16. Kriangkum J., Taylor B.J., Treon S.P., Mant M.J., Belch A.R., Pilarski L.M. Clonotypic IgM V/D/J sequence analysis in Waldenström macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004, 104:2134-2142.
17. Sahota S.S., Babbage G., Weston-Bell N.J. CD27 in defining memory B-cell origins in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009, 9:33-35.
18. San Miguel J.F., Vidriales M.B., Ocio E., et al. Immunophenotypic analysis of Waldenström's macroglobulinemia. Semin Oncol 2003, 30:187-195.
19. Konoplev S., Medeiros L.J., Bueso-Ramos C.E., Jorgensen J.L., Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin Pathol 2005, 24:414-420.
20. Tournilhac O., Santos D.D., Xu L., et al. Mast cells in Waldenström's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006, 17:1275-1282.
21. Elsawa S.F., Novak A.J., Grote D.M., et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia. Blood 2006, 107:2882-2888.
22. Schop R.F., Kuehl W.M., Van Wier S.A., et al. Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002, 100:2996-3001.
23. Ocio E.M., Schop R.F., Gonzalez B., et al. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 2007, 36:80-86.
24. Chang H., Qi C., Trieu Y., et al. Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma 2009, 9:36-38.
25. Leleu X., Hunter Z.R., Xu L., et al. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenström macroglobulinemia. Br J Haematol 2009, 145:59-63.
26. Braggio E., Keats J.J., Leleu X., et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenström's macroglobulinemia. Cancer Res 2009, 69:3579-3588.
27. Adamia S., Crainie M., Kriangkum J., Mant M.J., Belch A.R., Pilarski L.M. Abnormal expression of hyaluronan synthases in patients with Waldenström's macroglobulimenia. Semin Oncol 2003, 30:165-168.
28. Adamia S., Reichert A.A., Kuppusamy H., et al. Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenström macroglobulinemia. Blood 2008, 112:5111-5121.
29. Roccaro A.M., Sacco A., Chen C., et al. MicroRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood 2009, 113:4391-4402.
30. Vacca A., Dammacco F. MicroRNAs to know in Waldenström macroglobulinemia. Blood 2009, 113:4133-4134.
31. Singh A., Eckardt K.U., Zimmermann A., et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 1993, 91:251-256.
32. Crisp D., Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 1982, 72:915-922.
33. Gertz M.A., Merlini G., Treon S.P. Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Program 2004, 257-282.
34. Mehta J., Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 2003, 29:467-471.
35. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009, 145:151-163.
36. Bing J., Neel A. Two cases of hyperglobulinemia with affection of the central nervous system on a toxi-infection basis. Acta Med Scand 1936, 88:492-506.
37. Dammacco F., Sansonno D., Piccoli C., Tucci F.A., Racanelli V. The cryoglobulins: an overview. Eur J Clin Invest 2001, 31:628-638.
38. Faber C.G., Notermans N.C., Wokke J.H., Franssen H. Entrapment in anti-myelin-associated glycoprotein neuropathy. J Neurol 2009, 256:620-624.
39. Lunn M.P., Crawford T.O., Hughes R.A., Griffin J.W., Sheikh K.A. Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. Brain 2002, 125:904-911.
40. Gertz M.A. Management of cold haemolytic syndrome. Br J Haematol 2007, 138:422-429.
41. Palladini G., Russo P., Bosoni T., et al. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clin Lymphoma Myeloma 2009, 9:80-83.
42. Gertz M.A., Kyle R.A., Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. J Clin Oncol 1993, 11:914-920.
43. Gertz M.A., Kyle R.A. Amyloidosis with IgM monoclonal gammopathies. Semin Oncol 2003, 30:325-328.
44. Wechalekar A.D., Lachmann H.J., Goodman H.J., Bradwell A., Hawkins P.N., Gillmore J.D. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008, 112:4009-4016.
45. Alexanian R., Weber D., Delasalle K., Cabanillas F., Dimopoulos M. Asymptomatic Waldenström's macroglobulinemia. Semin Oncol 2003, 30:206-210.
46. Kyle R.A., Treon S.P., Alexanian R. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol 2003, 30:116-120.
47. Dimopoulos M.A., Gertz M.A., Kastritis E., et al. Update on treatment recommendations from the Fourth International Workshop on Waldenström's Macroglobulinemia. J Clin Oncol 2009, 27:120-126.
48. Kyle R.A., Greipp P.R., Gertz M.A., et al. Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000, 108:737-742.
49. Dimopoulos M.A., Kantarjian H., Weber D., et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994, 12:2694-2698.
50. Hellmann A., Lewandowski K., Zaucha J.M., Bieniaszewska M., Halaburda K., Robak T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur J Haematol 1999, 63:35-41.
51. Dhodapkar M.V., Jacobson J.L., Gertz M.A., Crowley J.J., Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenström's macroglobulinemia: an update of a US intergroup trial (SWOG S9003). Semin Oncol 2003, 30:220-225.
52. Foran J.M., Rohatiner A.Z., Coiffier B., et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma. Waldenström's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999, 17:546-553.
53. Leleu X., Soumerai J., Roccaro A., et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009, 27:250-255.
54. Dhodapkar M.V., Hoering A., Gertz M.A., et al. Long-term survival in Waldenström macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 2009, 113:793-796.
55. Treon S.P. How I treat Waldenström macroglobulinemia. Blood 2009, 114:2375-2385.
56. Gertz M.A., Rue M., Blood E., Kaminer L.S., Vesole D.H., Greipp P.R. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004, 45:2047-2055.
57. Treon S.P., Emmanouilides C., Kimby E., et al. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol 2005, 16:132-138.
58. Ghobrial I.M., Fonseca R., Greipp P.R., et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004, 101:2593-2598.
59. Treon S.P., Branagan A.R., Ioakimidis L., et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009, 113:3673-3678.
60. Laszlo D., Andreola G., Rigacci L., et al. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 2010, 28:2233-2238.
61. Dimopoulos M.A., Anagnostopoulos A., Kyrtsonis M.C., et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007, 25:3344-3349.
62. Buske C., Hoster E., Dreyling M., et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009, 23:153-161.
63. Ioakimidis L., Patterson C.J., Hunter Z.R., et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009, 9:62-66.
64. Treon S.P., Soumerai J.D., Branagan A.R., et al. Thalidomide and rituximab in Waldenström macroglobulinemia. Blood 2008, 112:4452-4457.
65. Treon S.P., Soumerai J.D., Branagan A.R., et al. Lenalidomide and rituximab in Waldenström's macroglobulinemia. Clin Cancer Res 2009, 15:355-360.
66. Treon S.P., Patterson C.J., Kimby E., Stone M.J. Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden. Clin Lymphoma Myeloma 2009, 9:10-15.
67. Chen C.I., Kouroukis C.T., White D., et al. Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1570-1575.
68. Treon S.P., Hunter Z.R., Matous J., et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenström's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007, 13:3320-3325.
69. Ghobrial I.M., Hong F., Padmanabhan S., et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia. J Clin Oncol 2010, 28:1422-1428.
70. Treon S.P., Ioakimidis L., Soumerai J.D., et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009, 27:3830-3835.
71. Hunter Z.R., Boxer M., Kahl B., et al. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079. J Clin Oncol (ASCO Annual Meeting Proceedings) 2006, 24:7523.
72. Owen R., Rawstron A.C., Osterborg A. Activity of alemtuzumab in relapsed/refractory Waldenström's macroglobulinemia. Blood 2003, 102:644a.
73. Rummel M.J., von Gruenhagen U., Niederle N., et al. Bendamustine plus Rituximab versus CHOP plus Rituximab in the first-line treatment of patients with Waldenström's macroglobulinemia: first interim results of a randomized phase III study of the Studygroup Indolent Lymphomas (StiL). Proceedings of the 5th International Workshop on Waldenström's macroglobulinemia 2008, Abstract 139.
74. Ghobrial I.M., Roccaro A., Hong F., et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström's macroglobulinemia. Clin Cancer Res 2010, 16:1033-1041.
75. Ghobrial I.M., Gertz M., Laplant B., et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia. J Clin Oncol 2010, 28:1408-1414.
76. Kyriakou C., Canals C., Sibon D., et al. High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010, 28:2227-2232.
77. Kyriakou C., Canals C., Sureda A., et al. Allogeneic stem cell transplantation (allo-SCT) in the management of advanced Waldenstrom's macroglobulinemia (WM). Blood (ASH Annual Meeting Abstracts) 2007, 110:619.
78. Anagnostopoulos A., Hari P.N., Pérez W.S., et al. Autologous or allogeneic stem cell transplantation in patients with Waldenström's macroglobulinemia. Biol Blood Marrow Transplant 2006, 12:845-854.
79. Roccaro A.M., Leleu X., Sacco A., et al. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res 2008, 14:1849-1858.
80. Roccaro A.M., Sacco A., Husu E.N., et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenström's macroglobulinemia. Blood 2010, 115:559-569.
81. Roccaro A.M., Sacco A., Aujay M., et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenström macroglobulinemia. Blood 2010, 115:4051-4060.
82. Morel P., Duhamel A., Gobbi P., et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood 2009, 113:4163-4170.
83. Gobbi P.G., Baldini L., Broglia C., et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?. Clin Cancer Res 2005, 11:1786-1790.
84. Morel P., Monconduit M., Jacomy D., et al. Prognostic factors in Waldenström's macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000, 96:852-858.
85. Ghobrial I.M., Fonseca R., Gertz M.A., et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenström macroglobulinaemia. Br J. Haematol 2006, 133:158-164.